|Advanced-stage cHL: Rethinking Our Options in Frontline Therapy|
Jonathon B. Cohen, MD, MS
|Release Date: October 17, 2018|
Expiration Date: October 17, 2019
|New strategies are emerging to improve the frontline treatment of patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL). In this interview, Dr. Jonathon Cohen discusses results from recent clinical trials that are making an impact on the frontline management of advanced-stage cHL. He also outlines how these advances will influence clinical practice and positively impact current standards of care for the disease.|
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
|View Only, CE ExpiredView Only, No Credit|